Compare BXMT & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | TLX |
|---|---|---|
| Founded | 1966 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | BXMT | TLX |
|---|---|---|
| Price | $20.59 | $8.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $20.25 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.2M | 115.0K |
| Earning Date | 10-29-2025 | 01-01-0001 |
| Dividend Yield | ★ 9.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.62 | 0.04 |
| Revenue | $393,335,000.00 | ★ $664,225,558.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.51 | N/A |
| P/E Ratio | ★ $32.87 | $273.17 |
| Revenue Growth | N/A | ★ 55.35 |
| 52 Week Low | $16.51 | $8.76 |
| 52 Week High | $21.24 | $30.36 |
| Indicator | BXMT | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 74.50 | 34.46 |
| Support Level | $19.55 | $9.37 |
| Resistance Level | $20.67 | $10.03 |
| Average True Range (ATR) | 0.32 | 0.26 |
| MACD | 0.11 | -0.05 |
| Stochastic Oscillator | 98.43 | 2.25 |
Blackstone Mortgage Trust Inc is a real estate finance company involved in the origination and purchase of senior loans collateralized by commercial properties in North America, Europe, and Australia. The vast majority of the company's asset portfolio is comprised of floating rate loans secured by priority mortgages. These mortgages are mainly derived from office, hotel, and manufactured housing properties. A percentage of the collateralized real estate properties are located in New York, California, and the United Kingdom. Blackstone Mortgage Trust is managed by a subsidiary of The Blackstone Group and benefits from the market data provided by its parent company. Nearly all of Blackstone Mortgage Trust's revenue is generated in the form of interest income.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.